Alcresta Therapeutics Inc., a Warren-based developer of novel, enzyme-based products, announced Monday it has appointed Daniel Orlando its new CEO, effective immediately.
Orlando was also named to the company’s board of directors.
“On behalf of the board of directors, I am very pleased to welcome Daniel to Alcresta Therapeutics. Daniel is an accomplished leader with extensive knowledge of the global health care landscape. His deep understanding of commercialization, as well as strong clinical and regulatory insights, will be of great value to Alcresta,” said Jeremy Lack, partner at Athyrium Capital.
Orlando, who has more than 18 years of experience in executive roles, previously served as chief operating officer at Vericel Corp. Before that, he held business development, marketing and sales roles at Takeda and Abbott Laboratories.
“I am excited to join Alcresta during this early stage of commercial growth. Its mission of helping enterally fed patients reach their potential during times of critical nutritional need is such compelling work,” Orlando said.
